Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011.

  • Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million.
  • Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GAAP operating income of $22.9 million for the same period in 2010.
  • Full year non-GAAP operating income was $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010.
  • Cash, cash equivalents, short-term investments and restricted cash totaled $214.6 million at the end of the quarter.

    • "Our strong execution in 2011 has positioned us to enter 2012 with an extraordinary opportunity to maximize shareholder value. We generated positive operating cash flow, reacquired the full rights to the exenatide franchise, expanded the approved uses for BYETTA, and, most importantly, positioned ourselves well to successfully launch BYDUREON in the U.S. following its recent approval," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We will also work to secure a new partner for exenatide outside the U.S. to advance our commitment to diabetes patients around the world, and continue to invest strategically in value-driving opportunities while continuing our focus on financial discipline."

    Highlights of Amylin's Fourth Quarter and Recent Activities

  • Received U.S. Food and Drug Administration (FDA) approval for BYDUREON™ (exenatide extended-release for injectable suspension) – the first and only once-weekly medication approved in the U.S. and the European Union for the treatment of type 2 diabetes. BYDUREON will be available in pharmacies throughout the U.S. later this month.

    • '/>"/>
    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... May 17, 2013 Medical devices are any ... biological product. In light of their different mechanisms, actions ... much more complicated than drug trails due to their ... safety instead of evaluating both safety and efficacy (which ... (which is the same as the SFDA) evaluate MDs ...
    (Date:5/17/2013)... SAN DIEGO , May 17, 2013 /PRNewswire/ ... today that its Fast-Track Advanced Technology Small Business ... National Institute of Allergy and Infectious Diseases (NIAID), ... (NIH), supporting the development of novel human antibody ... S. aureus or Staph) infections, including methicillin-resistant ...
    (Date:5/17/2013)... 2013  Technology advances have had a profound ... a constantly evolving communication environment, companies need to ... with internal executives. It is challenging, however, to ... and tools that are part of today,s communication ... Best Practices, LLC explores the various internal communication ...
    Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2
    (Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...
    (Date:5/18/2013)... Wright, KY (PRWEB) May 18, 2013 ... with hearing loss should consider the legal protections they ... claim, when problems arise with their child’s treatment or ... today. , Since 1927, the American Speech-Language-Hearing Association has ... communication disorders and to promote treatment, such as cochlear ...
    (Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
    (Date:5/18/2013)... IL (PRWEB) May 18, 2013 The ... Oregon Gov. John A. Kitzhaber, M.D., (D) to sign ... law by prohibiting minors under the age of 18 ... would become the third state in the nation to ... have enacted similar indoor tanning bans for minors. Nationwide, ...
    (Date:5/18/2013)... The topics that will be covered in the ... scrum meetings, scrum artifacts, and scrum simulation (optional). One can ... , These trainings are suitable for business analysts, project managers, ... who will be a part of the Scrum team, people ... Agile and Scrum, but are unsure of what it is. ...
    Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
    ... Sophisticated prostate cancer treatment delivered in less than 90 seconds ... using new technology from Varian Medical Systems, DECATUR, ... center in Illinois, and the third in the,United States, to ... Systems (NYSE: VAR ). John Hosler, an,85-year-old prostate cancer ...
    ... at AHIP Institute July 18-20, WASHINGTON, June ... answers for health plans and health networks wrestling ... in outsourcing of,credentialing services., (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ... during the AHIP Institute, June 18-20,in San Francisco. ...
    ... octopuses has shed new light on how our brains ... the Department of Neurobiology at the Alexander Silberman Institute ... Why octopuses?, Octopuses and other related creatures, known as ... because they have relatively large brains and they can ...
    ... cells more readily than a commonly used colorectal cancer ... tumors, but with fewer side effects, MIT researchers have ... potent anticancer agent, but the newly investigated compound, known ... other body tissues from damage. , "This compound, the ...
    ... is a rare association between spontaneous hypoglycemia and ... islets. It was initially associated with abdominal soft ... described. , The pathogenesis of hypoglycemia in ... excessive consumption of glucose by what is typically ...
    ... vitro, AMD3100 has shown a significantly inhibitory effect on invasion ... be further enhanced at higher concentration. This study, performed by ... Jiao Tong University is described in a research article to ... of Gastroenterology. , Colorectal cancer (CRC) is one of the ...
    Cached Medicine News:Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 3Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 3Health News:Hebrew University research on octopuses sheds light on memory 2Health News:Hebrew University research on octopuses sheds light on memory 3Health News:MIT researchers see alternative to common colorectal cancer drug 2
    Micro 2000 suture forceps light-weight instruments with blue-colored anodized round handles, extremely light weight, well balanced, easy to handle, fatigueless working, easy to maintain, corrosion-re...
    Micro dressing forceps....
    Round tip, sharp all around, angled....
    30 Degree angle....
    Medicine Products: